Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 4Recruiting 2Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 62Gastrointestinal 46Genitourinary 23Breast 18Gynecologic 12Head & Neck 11Dermatologic 6Sarcoma 5Tumor-Agnostic 3Other solid neoplasm 3CNS 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 2Thyroid Neoplasms 1Prostatic Neoplasms 1Melanoma 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Chondrosarcoma 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 59Radiotherapy 37Magnetic Resonance Spectroscopy 32Radiosurgery 27Specimen Handling 23Cyclophosphamide 21pembrolizumab 20Nivolumab 20Radiation 17Carboplatin 12Biopsy 12Bevacizumab 11Vincristine 10Ipilimumab 10Cisplatin 10X-Rays 9Lomustine 8Irinotecan 8Immunoglobulin G 8Etoposide 8trametinib 7Disulfides 7AZD 6244 7pertuzumab 6atezolizumab 6abemaciclib 6Topotecan 6Proton Therapy 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × durvalumab × CNS × Clear all
NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT04538742 2025-12-08

DB-07

AstraZeneca

Phase 1/2 Active not recruiting
245 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡